Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells

Figure 2 PLK-inhibitor BI6727 induces apoptotis in Mz-Ch-1 cells. Cleavage of PARP in Mz-Ch-1 treated with the PLK-inhibitor BI6727 (200 nmol/L for 24 h), the cytostatic drug cisplatin (1 mmol/L for 24 h) or both components was assessed by Western blot analysis (A) and densitometric quantification followed by normalization to loading control actin and shown as foldchange compared to vehicle-treated cells (B, mean ± SEM, n = 2). PLK: Polo-like kinase; PARP: Poly(ADP-ribose) polymerase 1.